The Department of Health has published several collections of resources about COVID-19 vaccination, vaccine rollout, and clinical guidance from the Australian Technical Advisory Group on Immunisation (ATAGI). These resources are updated when new information is available, so GPs should ensure they have access to the latest versions.
Vaccine product information
ATAGI and the Cardiac Society of Australia and New Zealand (CSANZ) have released joint guidance on the risk of myocarditis and pericarditis following Pfizer vaccination following an observed risk observed in overseas studies, especially in males under 30 years of age after the second doses. The has been updated to reflect this.
The has been updated to include Capillary Leak Syndrome (CLS) as a contraindication for the AstraZeneca vaccine. Providers should be aware of the information contained in the PI and individuals with a known history of CLS should not be vaccinated with AstraZeneca.
Consent forms
Consent form:
Patient information sheets
Information on AstraZeneca:
Information on Pfizer:
After your AstraZeneca:
After your Pfizer:
Provider information on consent:
Frequently asked questions on the Taskforce Ivermectin recommendation:
Clinical guidance and decision guides
ATAGI Clinical guidance:
COVID-19 vaccine – Clinical considerations:
Selection of second dose in specific circumstances:
